• Company Description
  • ImpriMed provides a platform enabling oncologists to quickly identify which of the available drugs can provide the best clinical outcomes for current patients. Quantitative high-throughput lab testing and AI technology are combined in the platform to provide healthcare providers with a patient-specific, comprehensive personalized drug prediction profile. The platform was first launched in the veterinary oncology space at a higher speed than in the human oncology market. It has helped 200+ veterinary oncologists in 30 states to treat canine lymphoma and leukemia patients. Its experience in the veterinary market has paved the way for the company to launch the validated platform into the human oncology space. The 4 levels of the service are personalized prediction profile, immune profile, flow cytometry, and PARR.